Show simple item record

dc.contributor.authorFanti, Stefano
dc.contributor.authorBrigantii, Alberto
dc.contributor.authorEmmett, Louise
dc.contributor.authorFizazi , Karim
dc.contributor.authorGillessen, Silke
dc.contributor.authorGoffin, Karolien
dc.contributor.authorHadaschik, Boris A
dc.contributor.authorHerrmann, Ken
dc.contributor.authorKunikowska, Jolanta
dc.contributor.authorMaurer, Tobias
dc.contributor.authorMacLennan, Steven
dc.contributor.authorMottet, Nicolas
dc.contributor.authorMurphy, Declan G
dc.contributor.authorOprea-Lager, Daniela E.
dc.contributor.authorO’Sullivan, Joe M
dc.contributor.authorOyen, Wim JG
dc.contributor.authorRouvière, Olivier
dc.contributor.authorSartor, Oliver
dc.contributor.authorStenzl, Arnulf
dc.contributor.authorVan Poppel, Hendrik
dc.contributor.authorWalz, Jochen
dc.contributor.authorWitjes, Wim
dc.contributor.authorBjartell, Anders
dc.date.accessioned2024-02-07T08:17:10Z
dc.date.available2024-02-07T08:17:10Z
dc.date.issued2022-10-01
dc.identifier215607276
dc.identifier544f695a-1b17-4420-bc9d-b6ec3dce30f1
dc.identifier85139488755
dc.identifier35697600
dc.identifier.citationFanti , S , Brigantii , A , Emmett , L , Fizazi , K , Gillessen , S , Goffin , K , Hadaschik , B A , Herrmann , K , Kunikowska , J , Maurer , T , MacLennan , S , Mottet , N , Murphy , D G , Oprea-Lager , D E , O’Sullivan , J M , Oyen , W JG , Rouvière , O , Sartor , O , Stenzl , A , Van Poppel , H , Walz , J , Witjes , W & Bjartell , A 2022 , ' EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy ' , European Urology Oncology , vol. 5 , no. 5 , pp. 530-536 . https://doi.org/10.1016/j.euo.2022.05.003en
dc.identifier.issn2588-9311
dc.identifier.otherORCID: /0000-0002-2691-8421/work/114480386
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/20070
dc.descriptionFunding support and role of sponsor: The EAU/EANM PSMA-based imaging and therapy consensus meeting was supported by an unrestricted educational grant from Novartis; Novartis had no influence over the content of the meeting or the publication. Medical writing support was funded by the European Association of Urology Research Foundation. Acknowledgements: The authors acknowledge Emily Spieker (Management Assistant, European Association of Urology) for project management. Medical writing support was provided by Angela Corstorphine of Kstorfin Medical Communications (KMC) limited.en
dc.format.extent7
dc.format.extent269903
dc.format.extent1556571
dc.language.isoeng
dc.relation.ispartofEuropean Urology Oncologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectComputed tomographyen
dc.subjectConsensusen
dc.subjectDiagnosisen
dc.subjectLutetiumen
dc.subjectPatient selectionen
dc.subjectPositron emission tomographyen
dc.subjectProstate canceren
dc.subjectPSMAen
dc.subjectRadioactive traceren
dc.subjectTherapyen
dc.subjectProstate-specific membrane antigenen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleEAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Academic Urology Uniten
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1016/j.euo.2022.05.003
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85139488755&partnerID=8YFLogxKen
dc.identifier.vol5en
dc.identifier.iss5en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record